This aligns with the development of TEAD palmitoylation inhibitors that target the downstream Hippo pathway effector, currently in phase I/II trials for NSCLC (129).Similarly, protein arginine methyltransferase 6 (PRMT6) promotes glycolysis and cisplatin resistance by methylating metabolic enzymes 6PGD and ENO1. Here, ENO1 is linked to non-small cell lung carcinoma.